Grant of Interim Extension of the Term of U.S. Patent No. 4,650,787; Sanvar®, 17877 [E7-6698]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 68 / Tuesday, April 10, 2007 / Notices
cprice-sewell on PROD1PC66 with NOTICES
and reissue patents as appropriate.
Under 37 CFR 1.510–1.570 and 37 CFR
1.902–1.997, the USPTO may grant
requests for ex parte and inter partes
reexamination proceedings. The public
uses this collection to request
corrections of errors in issued patents,
to request reissue patents, to request
reexamination proceedings, and to
ensure that the necessary fees and
documentation are submitted to the
USPTO. The USPTO is adding two
items to this information collection, an
electronic version of the Issue Fee
Transmittal (Form PTOL–85B) and a
petition to request an extension of time
in ex parte or inter partes reexamination
proceedings. This petition is an existing
requirement that was not previously
covered in this collection.
Affected Public: Individuals or
households, businesses or other forprofits, and not-for-profit institutions.
Frequency: On occasion.
Respondent’s Obligation: Required to
obtain or retain benefits.
OMB Desk Officer: David Rostker,
(202) 395–3897.
Copies of the above information
collection proposal can be obtained by
any of the following methods:
• E-mail: Susan.Fawcett@uspto.gov.
Include ‘‘0651–0033 copy request’’ in
the subject line of the message.
• Fax: 571–273–0112, marked to the
attention of Susan Fawcett.
• Mail: Susan K. Fawcett, Records
Officer, Office of the Chief Information
Officer, Customer Information Services
Group, Public Information Services
Division, U.S. Patent and Trademark
Office, P.O. Box 1450, Alexandria, VA
22313–1450.
Written comments and
recommendations for the proposed
information collection should be sent on
or before May 10, 2007 to David Rostker,
OMB Desk Officer, Room 10202, New
Executive Office Building, 725 17th
Street, NW., Washington, DC 20503.
Dated: April 3, 2007.
Susan K. Fawcett,
Records Officer, USPTO, Office of the Chief
Information Officer, Customer Information
Services Group, Public Information Services
Division.
[FR Doc. E7–6735 Filed 4–9–07; 8:45 am]
BILLING CODE 3510–16–P
VerDate Aug<31>2005
15:22 Apr 09, 2007
Jkt 211001
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2007–0014]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,650,787; Sanvar
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a third one-year interim extension of the
term of U.S. Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE.,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 23, 2007, Debiovision Inc.,
the exclusive agent of Debiopharm S.A.
and Debio Recherche Pharmaceutique
S.A., who is the exclusive licensee of
the Administrators of the Tulane
Educational Fund of New Orleans,
Louisiana, the patent owner, timely
filed an application under 35 U.S.C.
156(d)(5) for a third interim extension of
the term of U.S. Patent No. 4,650,787.
The patent claims the human drug
product Sanvar (vapreotide acetate).
The application indicates that a New
Drug Application for the human drug
product Sanvar (vapreotide acetate)
has been filed and is currently
undergoing regulatory review before the
Food and Drug Administration for
permission to market or use the product
commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional one year
as required by 35 U.S.C. 156(d)(5)(B).
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
17877
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent (April 25, 2007), a third
interim extension of the patent term
under 35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,650,787 is granted for a
period of one year from the extended
expiration date of the patent, i.e., until
April 25, 2008.
Dated: April 3, 2007.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E7–6698 Filed 4–9–07; 8:45 am]
BILLING CODE 3510–16–P
COMMISSION OF FINE ARTS
Notice of Meeting
The next meeting of the U.S.
Commission of Fine Arts is scheduled
for 19 April 2007, at 10 a.m. in the
Commission’s offices at the National
Building Museum, Suite 312, Judiciary
Square, 401 F Street, NW., Washington,
DC 20001–2728. Items of discussion
affecting the appearance of Washington,
DC, may include buildings, parks and
memorials.
Draft agendas and additional
information regarding the Commission
are available on our Web site: https://
www.cfa.gov. Inquiries regarding the
agenda and requests to submit written
or oral statements should be addressed
to Thomas Luebke, Secretary, U.S.
Commission of Fine Arts, at the above
address or call 202–504–2200.
Individuals requiring sign language
interpretation for the hearing impaired
should contact the Secretary at least 10
days before the meeting date.
Dated in Washington, DC, 4 April 2007.
Thomas Luebke,
Secretary
[FR Doc. 07–1772 Filed 4–9–07; 8:45 am]
BILLING CODE 6330–01–M
DEPARTMENT OF DEFENSE
Office of the Secretary
[No. DoD–2007–HA–0022]
Proposed Collection; Comment
Request
Office of the Assistant
Secretary of Defense for Health Affairs,
DoD.
ACTION: Notice.
AGENCY:
E:\FR\FM\10APN1.SGM
10APN1
]]>Agencies
[Federal Register Volume 72, Number 68 (Tuesday, April 10, 2007)]
[Notices]
[Page 17877]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-6698]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2007-0014]
Grant of Interim Extension of the Term of U.S. Patent No.
4,650,787; Sanvar[reg]
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim
extension of the term of U.S. Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE., P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On March 23, 2007, Debiovision Inc., the exclusive agent of
Debiopharm S.A. and Debio Recherche Pharmaceutique S.A., who is the
exclusive licensee of the Administrators of the Tulane Educational Fund
of New Orleans, Louisiana, the patent owner, timely filed an
application under 35 U.S.C. 156(d)(5) for a third interim extension of
the term of U.S. Patent No. 4,650,787. The patent claims the human drug
product Sanvar[reg] (vapreotide acetate). The application indicates
that a New Drug Application for the human drug product Sanvar[reg]
(vapreotide acetate) has been filed and is currently undergoing
regulatory review before the Food and Drug Administration for
permission to market or use the product commercially.
Review of the application indicates that except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional one year as
required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the
regulatory review period will continue beyond the extended expiration
date of the patent (April 25, 2007), a third interim extension of the
patent term under 35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 4,650,787 is granted for a period of one year from the
extended expiration date of the patent, i.e., until April 25, 2008.
Dated: April 3, 2007.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E7-6698 Filed 4-9-07; 8:45 am]
BILLING CODE 3510-16-P
